Clinical trial
Olmesartan in Essential Hypertension
NCT00185172 · Sankyo Pharma Gmbh, Industry · Completed
Key facts
| NCT number | NCT00185172 |
|---|---|
| Title | Olmesartan in Essential Hypertension |
| Official title | Efficacy and Safety of Olmesartan: Reduction of Blood Pressure in the Treatment of Patients Suffering From Mild to Moderate Essential Hypertension |
| Lead sponsor | Sankyo Pharma Gmbh, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Essential Hypertension |
| Intervention type | Drug, Other |
| Interventions | placebo, olmesartan medoxomil, olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets |
| Enrollment | 2,333 |
| Start date | Jan 1, 2002 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Sep 16, 2005 |
| Last update posted | Apr 29, 2008 |
| Countries | Austria, Germany, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: